UBS Group
RYTM icon

UBS Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

UBS Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,100
Closed -$429K – 10763
2025
Q1 		$429K Buy
+8,100
New +$449K ﹤0.01% 5968

Other funds holding RYTM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group's RYTM Position: Q3 2026 in Review

UBS Group increased its Rhythm Pharmaceuticals (RYTM) stake by 118% in Q3 2026, buying an estimated $18.2M and bringing the position to 314,952 shares worth $30M. The position accounts for ﹤0.01% of the portfolio, ranked #2216.

UBS Group first reported a position in RYTM in Q4 2017 and has held it in 36 quarters since. The position peaked at $45.7M in Q4 2025. 239 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • UBS Group held 314,952 shares of Rhythm Pharmaceuticals worth $30M as of Q3 2026.
  • UBS Group bought 170,574 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $18.2M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #2216 holding.
  • UBS Group first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 36 quarters since.
  • UBS Group's Rhythm Pharmaceuticals position peaked at $45.7M in Q4 2025.
  • 239 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.